TenNor reports top-line Phase IIa results for rifaquizinone in PJI

TenNor Therapeutics has reported positive top-line data from a Phase IIa trial assessing rifaquizinone in patients with PJI. Following the Phase IIa results, TenNor has begun a multi-centre Phase IIb trial after approval from China’s regulator. The study focused on early, acute or chronic PJI, with TNP-2092 delivered via intra-articular injection. Credit: KongNoi / Shutterstock.com. TenNor Therapeutics has reported positive top-line data from a Phase IIa trial assessing its drug candidate, rifaquizinone (TNP-2092), in patients with periprosthetic joint infection (PJI). Conducted in China, the study focused on patients with early, acute or chronic PJI, with TNP-2092 delivered via intra-articular injection…

Source: Clinical Trials Arena